methylprednisolone + prednisone (Thomas Jefferson University)

The term **steroids-Thomas Jefferson University-liver transplantation** refers to the corticosteroid-based immunosuppressive regimen used as the control arm in a Phase 4 clinical trial (NCT00160342) conducted by Thomas Jefferson University. This regimen consists of methylprednisolone (Solu-Medrol) administered intravenously during the anhepatic phase and tapered over the first five days post-transplant, followed by oral prednisone starting on day six. The prednisone is then gradually tapered and completely weaned off by six months post-operation. These glucocorticoids function by binding to the glucocorticoid receptor, thereby suppressing the immune response to prevent graft rejection. This standard-of-care arm was compared against a steroid-free regimen (basiliximab, tacrolimus, and mycophenolate sodium) to evaluate graft survival and the incidence of steroid-related complications such as hypertension, diabetes, and osteoporosis in adult primary liver transplant recipients.

Brand names

Solu-Medrol

Other names

methylprednisoloneprednisoneSolumedrolcorticosteroidsglucocorticoidssteroids-Thomas Jefferson University-liver transplantation